Clinical Trial

Disease: Solid Tumors (NCT03970382)

Disease info:

A solid tumour is an abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumours may be benign (not cancer), or malignant (cancer). Solid tumour types are named according to the type of cell they originate from. Examples of solid tumours are sarcomas, carcinomas, and lymphomas. Leukaemias (cancers of the blood) generally do not form solid tumours. 

Based on projections, cancer deaths will continue to rise with an estimated 11.4 million cancer-related deaths per year in 2030.
Official title:
A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic Solid Tumors

PACT Pharma, Inc.


PACT Pharma, Inc.


United States, CaliforniaCity of Hope
Duarte, California, United States, 91010University of California, Los Angeles
Los Angeles, California, United States, 90024University of California, Irvine Medical Center
Orange, California, United States, 92868University of California, Davis
Sacramento, California, United States, 95817University of California, San Francisco
San Francisco, California, United States, 94158United States, IllinoisNorthwestern University Medical Center
Chicago, Illinois, United States, 60611United States, New YorkMemorial Sloan Kettering Cancer Center
New York, New York, United States, 10065United States, TennesseeTennessee Oncology
Nashville, Tennessee, United States, 37203United States, WashingtonFred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109

Study start:
Jul. 13, 2019
Gene editing method:
Type of edit:
Gene knock-out and insertion
Knock-out of TCRα (TRAC) and TCRβ (TRBC) genes, and insertion of genes encoding the two chains of a neoantigen-specific TCR (neoTCR) in in the TRAC locus .
Delivery method:
- Ex-vivo
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Unknown


This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.

The investigational agent in this protocol is NeoTCR P1, an autologous adoptive T cell therapy (ACT) for patients with solid cancer. NeoTCR P1 is composed of apheresis derived CD8 and CD4 T cells that are precision genome engineered to express one autologous TCR of native sequence that targets a neoepitope (neoE) presented by human leukocyte antigen (HLA) receptors exclusively on the surface of that patient's tumor cells and not on other cells in the body.

Last updated: Nov. 16, 2022
Search CRISPR Medicine